Physician profile
Sandra Y Robles
NPI 1992760540
$3,528.35
in general payments reported to CMS, 2019-2025
21 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $51.77 · 2021: $39.75 · 2022: $347 · 2023: $753 · 2024: $928 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,812.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,065.10 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $512.35 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $395.53 | 2019-2025 | Wegovy, Ozempic |
| Abbvie INC. | $311.57 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Phathom Pharmaceuticals, INC. | $239.84 | 2024-2025 | Voquezna |
| Amgen INC. | $173.18 | 2019-2024 | Otezla, Repatha |
| Pfizer INC. | $168.76 | 2024-2025 | |
| Lilly USA, LLC | $122.42 | 2019-2025 | Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $120.61 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $120.02 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $102.90 | 2022 | |
| Janssen Pharmaceuticals, INC | $37.27 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $31.10 | 2019-2020 | |
| Abbott Laboratories | $24.58 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.38 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $16.86 | 2019 | |
| Merck Sharp & Dohme LLC | $15.14 | 2019 | |
| Boston Scientific Corporation | $12.87 | 2019 | |
| Flowonix Medical Incorporated | $11.61 | 2019 | |
| Sanofi Pasteur INC. | $11.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Robles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.